Blood Thinners: DOACs vs Warfarin and New Alternatives in
Quick Facts
What Blood Thinner Options Exist in 2026?
DOACs
- Apixaban (Eliquis): Twice daily. Lowest bleeding risk among DOACs.
- Rivaroxaban (Xarelto): Once daily. Convenient.
- Edoxaban (Savaysa): Once daily. Good safety profile.
- Dabigatran (Pradaxa): Twice daily. Has specific reversal agent (idarucizumab).
Traditional
- Warfarin: Required for mechanical valves. Needs INR monitoring.
- Heparin/LMWH: Injectable, hospital/pregnancy use.
DOACs now account for the majority of anticoagulant prescriptions. Apixaban is the most prescribed worldwide.
DOACs vs Warfarin
DOAC Advantages
- Approximately 50% fewer intracranial hemorrhages (per meta-analysis of major DOAC trials)
- No INR monitoring
- Fewer drug/food interactions
- Fixed dosing
- Full effect in 2-4 hours
Warfarin Preferred
- Mechanical heart valves
- Antiphospholipid syndrome
- Severe renal impairment (CrCl <15)
- Cost constraints in some regions
What Are Factor XI Inhibitors?
Factor XI plays a greater role in pathological clotting than in normal wound healing, making it an attractive drug target:
- Abelacimab: Monthly injection. Showed significant reduction in stroke and systemic embolism with very low bleeding rates in the AZALEA-TIMI 71 trial.
- Asundexian: Oral, once daily. Phase 2 trials showed promise, but the Phase 3 OCEANIC-AF trial was discontinued due to lack of efficacy vs apixaban. Future development uncertain.
- Milvexian: Oral. In Phase 3 trials for stroke prevention.
An estimated 30-40% of atrial fibrillation patients who could benefit from anticoagulation remain untreated, often due to bleeding concerns.
Frequently Asked Questions
Among DOACs, apixaban has shown the lowest rates of major bleeding in clinical trials. But the best choice depends on kidney function, age, and other medications.
Moderate alcohol is generally considered acceptable on DOACs. With warfarin, alcohol can unpredictably affect INR levels. Heavy drinking increases bleeding risk with all anticoagulants.
Take when remembered unless close to next dose. Never double up. Check the specific guidance for your medication.
No. Anticoagulants prevent new clots from forming and stop existing clots from growing. The body's own fibrinolytic system dissolves existing clots over time.
No supplement has been shown to match the efficacy of prescription anticoagulants. Never stop medications without consulting your doctor.
References
- Granger CB, et al. Apixaban vs Warfarin (ARISTOTLE). NEJM. 2011;365:981-992.
- Patel MR, et al. Rivaroxaban vs Warfarin (ROCKET AF). NEJM. 2011;365:883-891.
- Ruff CT, et al. DOACs vs warfarin meta-analysis. The Lancet. 2014;383:955-962.
- Connolly SJ, et al. Dabigatran vs Warfarin (RE-LY). NEJM. 2009;361:1139-1151.
- Verhamme P, et al. Abelacimab in Atrial Fibrillation (AZALEA-TIMI 71). NEJM. 2024.